Company
Headquarters: Marcy l'Etoile, France
Employees: 13,000
CEO: Mr. Alexandre Merieux
€11.10 Billion
EUR as of July 1, 2024
US$11.92 Billion
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $204.45 B |
Danaher | $177.21 B |
Siemens Healthineers AG | $63.84 B |
DexCom, Inc. | $45.21 B |
Lonza Group Ltd | $39.85 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
bioMérieux S.A. develops and produces in vitro diagnostic solutions for private and hospital laboratories for the diagnosis of infectious diseases. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
BioMérieux SA has the following listings and related stock indices.
Stock: Euronext: BIM wb_incandescent
Stock: FSX: EYWN wb_incandescent